https://scholars.lib.ntu.edu.tw/handle/123456789/638485
標題: | New Biological Approaches in Asthma: DNA-Based Therapy | 作者: | LI-CHIEH WANG JYH-HONG LEE YAO-HSU YANG YU-TSAN LIN BOR-LUEN CHIANG |
關鍵字: | antisense oligonucleotides | Asthma | CpG | cytokine | gene therapy | Th1/Th2 | 公開日期: | 1-一月-2012 | 卷: | 6 | 來源出版物: | Frontiers in Medicinal Chemistry | 摘要: | Asthma is characterized by airway inflammation, bronchial hyper-responsiveness, and reversible airway obstruction. Medications for asthma include corticosteroids, β2-adrenergic receptor agonists, chromones, methylxanthines, and leukotriene modifiers. Despite these advances in therapy, many symptoms are not well controlled. Since asthma is a chronic airway inflammation with a bias towards a type 2 T helper (Th2) cell response, some new approaches are targeted towards the Th2 inflammation pathway. These include anti-IgE therapy, anti-Th2 cytokine therapy, and therapies aiming at increasing Th1 cytokines. This article will focus on DNA-based therapy, a novel therapeutic strategy for asthma. Immunostimulatory gene therapy using CpG oligodeoxynucleotides with central deoxycytidyl-deoxyguanosine (CpG) dinucleotide, in which the cytosine nucleobase is unmethylated, can stimulate the innate immunity and augment Th1 response. With DNA gene therapy, genes can be introduced to target Th1 cytokines or other mediators in the airway in order to counteract Th2 inflammation in asthma. Also, antisense oligonucleotides can target mRNA species of interest in asthma. Through these therapies, we can expect long-lasting effects, better control of symptoms, and reducing medication in the future. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638485 | ISBN: | 9781608054640 | ISSN: | 15672042 | DOI: | 10.2174/9781608054640113060011 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。